Skip to content
lifestyle.ideacrossing.org
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Entera Bio Ltd.
ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera’s Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis)
June 15, 2026
Entera’s EB613, First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis – Single Tablet Data Selected for Late Breaking Oral Presentation at ENDO 2026 Annual Meeting; Additional Oral Peptide Pipeline Data Accepted for Presentation
May 28, 2026
Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs
May 24, 2026
Entera Bio to Host Key Opinion Leader Webinar Highlighting the Osteoporosis Treatment Landscape and the Opportunity for EB613
May 20, 2026
Entera Bio Announces Pricing of $10.0 Million Direct Investment by BVF Partners with Potential for up to $24.5 Million in Total Proceeds
April 28, 2026